Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Neurocrine Bio. (NBIX) PT Lowered to $105 at Cowen
February 6, 2019 7:54 AM ESTCowen analyst Phil Nadeau lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $115.00) while maintaining a Outperform rating.
The analyst commented, "NBIX reported Q4 Ingrezza sales of $130.3MM, consistent with its January pre-announcement. Results from NBI-74788's Ph. IIa in CAH... More
